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Background: Site-independent review of subject eligibility for central nervous system (CNS) trials has been used as a
surveillance method to enhance the integrity and precision of the subject selection process. We evaluated the utility of
a customized review strategy that employs site-independent review of audio-digital recordings of site-based screen
interviews.
Methods: We applied a customized site-independent subject selection strategy in nine phase II double-blind,
placebo-controlled clinical trials across the CNS spectrum. The Clinical Validation Inventory for Study Admission
(C-VISATM, Boston, MA, USA) was developed as a site-independent review method that evaluates and confirms diagnoses,
symptom severity, and subject validity prior to enrollment (randomization) into a clinical trial. The C-VISATM method
uses audio-digital recordings of actual site-based interviews conducted at the screening visit. The recordings of these
interviews accompanied by digital notes are electronically submitted for independent review and ‘dual’ scoring of key
rating instruments. A multi-tiered system of site-independent reviewers either affirms subject eligibility or identifies
administrative and/or clinical issues that may preclude study eligibility (screen failure).
Results: In this meta-analysis, 404 of 2,515 submitted C-VISATM eligibility reviews (16.1%) were challenged by tier 1
reviewers and escalated to a tier 2 reviewer. After telephone adjudication with the respective trial site investigator, 168 of
these 404 tier 2 reviews (41.6%) were not approved yielding an overall screen fail rate of 6.7% for all C-VISATM submissions.
The primary reasons for screen failure were insufficient documentation to support the intended diagnosis, symptom
severity that did not meet protocol criteria, the presence of excluded comorbid conditions, and potential confounding
factors that might obscure assessment during the trial.
Conclusion: The C-VISATM review process coupled with dual independent scoring of key rating instruments is a quality
assurance strategy that provides a systematic site-independent eligibility filter to enhance the precision of subject selection
and the integrity of study data. The C-VISATM strategy has broad applicability across the CNS spectrum because it achieves
the objective of confirmatory site-independent review without producing excessive site or subject burden.
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Central nervous system (CNS) drug development has
been challenged by the frequent failure to achieve signal
detection in many clinical trials [1-7]. Numerous factors
affect trial outcomes including the effectiveness of the
candidate drug, study design, study completion, and trial
execution [6-8]. Two important trial execution factors are
subject selection and ratings precision [6-12]. Inappropriate
subject selection and inaccurate ratings reduce the
statistical power to achieve signal detection [13-15].
Appropriate subject selection is a complex process that
requires collection of accurate documentation and reliable
symptomatic measurements at a time when the potential
study subject is often least well known to the site (screening)
and often most disturbed (ill). Potential study candidates
may be unfamiliar with study procedures and arbitrarily
endorse symptoms or exaggerate severity in order to gain
entry into the clinical trial. Misplaced site-based incentives
(e.g., financial, humanitarian, and competitive interests) may
also influence subject selection because clinical trial sites are
generally incentivized to enroll rather than reject subjects
[6,7,16-18]. Further, there may be concurrent, confounding
factors or comorbid conditions that might adversely
affect the reliability of symptom severity ratings during
the course of the clinical trial [11]. For instance, accurate
assessments might be obscured in study candidates who
have experienced recent trauma or other de-stabilizing
environmental conditions (e.g., unstable housing, family
discord, recent job loss). Consequently, subject selection
for CNS trials is a complex, risky process that requires
more careful attention and scrutiny.
The inherent challenges of subject selection have
generated a compelling argument to use a ‘dual’ eligibility
strategy that combines site-independent reviews as
unbiased ‘second’ opinions in conjunction with the
site-based assessments. Site-independent reviews attempt
to manage the potential for insufficient documentation,
incomplete interviews, inaccurate diagnoses, or inflated
screen scores [8,11,18-20]. These reviews are quality
assurance surveillance ‘filters’ that improve the integrity
and precision of subject selection. It has been shown that
assessment and reliability improve when more than one
rater assesses the same subject and provides a second
opinion [14,21]. The mere awareness of a secondary
review (surveillance) can often improve the quality of the
initial site-based assessment as well.
Site-independent clinical assessments by live telephone,
audio, or video interviews have been used across the
CNS spectrum for many years [8,22-26]. These exter-
nal assessments increase the time and the cost of
doing a study and can add considerable site-burden
and resistance as well. Consequently, an external eli-
gibility review strategy must be reasonably balanced
between the objective of enhancing subject selectionand the need to sustain the engagement of the subject and
collaboration of the trial site.
A subject who is truly appropriate (‘valid’) for enrollment
in a clinical trial must meet additional selection criteria
that exceed the conventional protocol entry criteria of
most CNS trials such as excluding subjects with potentially
confounding (de-stabilizing) conditions that may obscure
assessment [11,27,28]. Most surveillance strategies do not
assess the appropriateness (‘validity’) of subjects for partici-
pation in a clinical trial. The SAFER criteria inventory was
introduced as an external review strategy to affirm validity
of subjects for CNS clinical trials [11,19]. The SAFER
assessment is administered as a telephone interview by a
site-independent clinician between the screen and baseline
visit and requires extra site and subject time for scheduling
and coordination [11,19]. As an entirely separate interview,
the SAFER interview is subject to informational and
temporal variance because the remote SAFER telephone
interviewer may obtain different responses from a subject
who may be more or less informative relative to the
preceding ‘live’ site-based assessment.
An alternative method to obtain a second opinion
about subject eligibility is to record and independently
assess the actual screen interviews conducted by the
site-based rater. For instance, Schoemaker and colleagues
used laptop computers with inbuilt cameras to record some
site-based assessments [20]. In their system, recorded inter-
views were transmitted over the web via a secure server for
site-independent review of symptom severity [20]. This
method eliminated both temporal and informational vari-
ance between site-based and independent raters because
both raters evaluated exactly the same information.
This paper describes the application of a recording strat-
egy for site-independent review. The Clinical Validation
Inventory for Study Admission (C-VISATM, Houston, TX,
USA) uses audio-digital recordings of key site-based
screening assessments as the basis for site-independent
subject eligibility review. The recordings facilitate a dual
screening assessment by using site-independent clinicians
to review the actual site-based screening interviews.
This external review strategy was developed to enhance
the reliability of subject selection for CNS trials with a
procedure that could be applied in large global clinical
trials and would not require extra time or site burden.
The aim of this paper was to examine the utility of
the C-VISATM dual review eligibility process in nine
double-blind, placebo-controlled clinical trials conducted
across the CNS spectrum including studies of subjects
with major depressive disorder (MDD), schizophrenia,
and Alzheimer's disease (AD).
Methods
Audio-digital recordings and customized C-VISATM
screening assessment batteries were used as part of the
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placebo-controlled clinical trials conducted across the
CNS spectrum. The data from these studies were
merged for this meta-analysis and include two studies
of patients with MDD, five studies in subjects with
schizophrenia, and two studies of mild-moderate
Alzheimer's disease. Clinical trial sites from the United
States, Canada, Europe, and Asia participated in these
studies. All potential study subjects signed a written
consent approved by an institutional review board that
included consent to audio-digital recording of key screen
assessments using a customized C-VISATM workbook as
part of the screening process. A trained, site-based rater
administered the C-VISATM assessment battery (described
below) using a commercially available audio-digital pen.
The recordings were electronically transmitted via a
secure website to Clintara LLC (Boston, MA, USA)
who coordinated a multi-layered site-independent review
process. The external review process included both
administrative review for completeness and two tiers of
clinical review to evaluate subject eligibility.
Development of the C-VISATM
The C-VISATM contains study-specific screening
instruments and a customized worksheet developed for
investigators to summarize the clinical entry criteria
supporting subject eligibility. This documentation may
include evidence gathered from multiple sources. The
C-VISATM was derived, in part, from the principles used
to develop the SAFER validity criteria and the concept of
validity as described by Kendell and Jablensky to ascertain
whether a subject's clinical presentation and recent history
is ‘rare’ enough (valid) to be appropriate for a specific
clinical trial [11,27].
A customized C-VISATM workbook was developed for
each of the nine studies in this analysis based upon
protocol-specific criteria. Each C-VISATM included a battery
of assessment components:
a) A diagnostic screening module that was either a
historical narrative or validated screening
instrument such as the Mini International
Neuropsychiatric interview (M.I.N.I.) or Structured
Clinical Interview for DSM-IV, Structured Clinical
Interview for DSM diagnoses (SCID) [29,30]
b) A clinician-administered symptom severity
questionnaire identifying and quantifying current
clinical symptoms related to the symptom severity
thresholds as delineated in the protocol
c) A narrative impression of global illness severity that
documented the impact of current symptoms on
behavior and function [12]
d) A C-VISATM summary worksheet customized to
address all inclusion and exclusion criteria andexplore potential confounding (or destabilizing) factors
and reliability issues that might obscure assessment [31]
In each study, the customized C-VISATM summary
worksheet required documentation to affirm that the
subject was truly appropriate (valid) for the specific
study and met the following validity criteria:
1. Diagnostic verification. A clinical presentation that
met diagnostic criteria and had face validity
consistent with the typical course of the underlying
disease state
2. Symptom severity confirmation. Sufficient acute
symptom severity that scored within the entry
criteria thresholds established by the protocol
3. Reliable and measurable symptoms. Sufficient,
measurable symptoms based upon the selected
rating instruments that might be sensitive to change
during the specified time interval and could be
reliably assessed with the subject (and informant as
needed) during the clinical trial
4. Absence of confounding factors. Subject did not have
any co-morbid conditions, excluded medications, or
confounding factors that might obscure meaningful
measurement of clinical change during the study
(e.g., substance abuse, recent trauma)
5. Clinical relevance. Sufficient documented evidence
that the current symptoms were clinically relevant
and warranted treatment intervention
Clinical relevance, as noted above, meant that the
presenting symptoms had some pathological impact and
were therefore consequential to the subject's behavior or
function. In studies involving psychosis or cognitive
impairment, the documentation of clinical relevance
required collateral information and/or corroboration
from a reliable informant.
Audio-digital recordings
Customized C-VISATM workbooks were designed to
work in conjunction with audio-digital pen recorders.
These writing instruments were commercially available
pens that have both audio recording and digital image
capture technologies. The customized C-VISATM
workbooks were manufactured on specialized paper
forms that capture the digital images (written notes)
which were uploaded with the audio recordings and
electronically transmitted via a secure website to Clintara
LLC for independent review.
Site-independent review process: implementation of
C-VISATM in a clinical trial
In all nine studies, the site-based raters obtained the
subject's consent to record the screening interviews
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the interviews. As described above, the site-based rater
notes were graphically digitized on specialized paper and
accompanied the audio recordings obtained with the
recording pen. In addition, the trial site investigator
(or designee) reviewed all of the available screening
information and completed the comprehensive C-VISATM
summary worksheet that reviewed and examined the
fundamental issues related to subject eligibility and validity.
The completed C-VISATM battery was uploaded via
a secure website to a central site (Clintara LLC) for
distribution for site-independent review. The site-
independent review process included an initial administra-
tive review for data completeness and a two-tiered clinical
review. Site-independent clinical reviewers were subcon-
tracted regional experts who were trained in the study
procedures and spoke the language of the raters. The
site-independent reviewers had extensive experience
in clinical trials with the designated study population
and completed the same rater-training program and
met the same qualification standards to conduct ratings as
the site-based raters. Clintara employed an internal quality
control program that included a random, secondary
independent review of the primary site-independent
reviewers (an independent review of the reviewers) to
affirm the sustained reliability of their assessments.
Site-independent reviewers were not affiliated with the
clinical trial site submitting the proposed study candidate
for the study. Site queries could occur at any point during
this layered review process to request further documenta-
tion or clarification about the submitted screen materials or
clinical queries. Clinical review included a primary clinical
reviewer (tier 1) who reviewed every subject submission and
a second clinical reviewer (tier 2) whenever there was a tier
1 eligibility challenge. The tier 2 review was an interactive
process that included adjudication (telephone discussion)
with the site investigator as part of a collaborative and
consultative process that was considered an essential part ofTable 1 Subject selection issues identified across the CNS spe
All reviewed subjects Challenged
(% of all cas
Inadequate documentation to support the diagnosis 68
Insufficient symptom severity (too low) 75
Symptom severity too high (above entry criteria) 44
Presence of comorbid medical diagnosis 30
Presence of comorbid psychiatric diagnosis 67
Substance abuse/dependence 29
External confounding factors 50
Unreliable/unassessable subject or informant 13
Other protocol-specific study criteria 28
Total of all submitted subjects (n = 2,515) 404the review process. The study charter authorized the site-
independent reviewer to make the final recommendation
regarding subject eligibility after telephonic adjudication
with the trial site investigator. The timeline objective
was to complete the site-independent review process
within 72 h of receipt of materials in order to facilitate the
randomization of appropriate subjects.
Results
Subject selection across all studies
Each of the nine studies included in this meta-analysis
experienced a high rate of administrative review when
the studies were initiated. Across the nine studies, the
rates of administrative review ranged from 50%–90%
of submissions within the first 6 months. Most of the
administrative issues related to insufficient documentation
could be corrected and thereby avoid later queries. In all
studies, the quality of interviews and submitted screen
data improved as a consequence of external review
and remediation. Consequently, the rate of administrative
reviews for incomplete documentation dropped consider-
ably as the study proceeded. The rates of administrative
review ranged from 25%–40% of submitted C-VISATM
batteries after the first 6 study months.
For this analysis, 2515 C-VISATM batteries passed
administrative review and were submitted for independent
clinical review. The mean time for final determination of
study eligibility across this entire sample of reviews was
55.8 ± 24.5 h (SD). The mean turnaround time included
the adjudication process with the trial site investigator.
The addition of the audio-digital recording requirement
and external review procedure did not affect the rate of
enrollment in these studies.
As shown in Table 1, tier 1 clinical reviewers challenged
404 of the C-VISATM reviews (16.1% of all submissions).
One hundred sixty-eight of these challenged reviews
(41.6%) were ultimately screen failed by tier 2 reviewers
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studies was 6.7% of all submitted reviews.
As noted in Table 1, the most common reasons for tier
2 escalations across all studies included inadequate
documentation to support the intended diagnosis, symp-
tom severity scores that did not fall within the protocol
criteria thresholds (either too high or too low), and the
presence of excluded comorbid medical or psychiatric
conditions. Potential confounding (or destabilizing) factors
that might obscure assessment of symptom severity
during the trial were another common reason for challen-
ging subject eligibility, particularly in the schizophrenia
studies. Confounding factors included recent exposure to
traumatic events, personal losses, unstable living conditions,
or relocation to a new area without social supports.
In addition, the independent reviewers identified some
inadequate interviews that led to rater remediation or
circumstances in which the informant (often the caregiver
for AD studies) was not reliable.
Sixty-eight cases (2.7%) were initially challenged
because of inadequate documentation to support the
diagnosis. Clinical queries asked for more information
about the onset and behavioral impact of symptoms,
documentation about current symptoms to meet diagnostic
criteria, or evidence of progressive decline (in Alzheimer's
disease studies). In more than 72% of cases, sufficient
documentation was provided to support the diagnosis
and approve the case. In contrast, only 42% of cases
challenged regarding symptom severity criteria were
ultimately approved (see Table 1). The reasons for tier
2 escalations varied somewhat by disease category and the
study-specific entry criteria, but the rates of challenge and
approval were largely consistent across the CNS spectrum.
Subject selection for depression studies
In the depression studies, the C-VISATM batteries
included review of the recorded diagnostic screening
instrument and dual scoring of the symptomatic severity
eligibility measurement. Excluded psychiatric diagnoses
(bipolar disorder or substance abuse) were identified in
2.5% of reviewed cases as part of the diagnostic assessments
but had been overlooked or minimized as relevant by the
site investigator prior to the tier 2 discussion. Further, dual
scoring of the recorded screen symptomatic questionnaires
identified 5.9% of subjects who were below the minimum
severity threshold for study entry (insufficient symptom
severity). Once informed via remediation, these putative
cases of score inflation were rarely repeated on subsequent
assessments by the same site-based rater.
Subject selection for schizophrenia studies
Data was analyzed from five separate studies of patients
with schizophrenia. In our analysis, 3.5% of these
patients presented with concomitant mood symptoms(and the possibility of schizoaffective disorder) that were
study exclusions and therefore challenged by tier 1
reviewers. Overall, tier 2 reviewers screen failed 2% of
all submissions for the schizophrenia studies because
of excluded comorbid psychiatric conditions.
These studies had a range of acceptable symptom
severity eligibility scores based upon the Brief Psychiatric
Rating Scale (BPRS) or Positive and Negative Syndrome
Scale (PANSS) total screen scores [32,33]. Four studies
sought patients with an acute exacerbation of psychosis
(with a minimum symptom severity threshold) whereas
one study sought patients with relatively stable illness
(with a maximum illness severity threshold). Dual
site-independent scores were based upon the audio
recordings of the BPRS or PANSS interviews with
accompanying corroborative digital notes. Dual scores
resulted in screen failures for 1.8% of patients because of
insufficient symptom severity and 1.0% because of excessive
severity exceeding protocol criteria thresholds.
In one study, we examined the trial outcome of 39
‘challenged’ subjects who achieved tier 2 approval
after adjudication and proceeded to randomization
(DeMartinis, personal communication). The completion
rate and trial outcome of these subjects in this study was
similar to the other 273 subjects who were unchallenged
by the tier 1 reviewers; 76% of all randomized subjects
completed the study, and 74% of randomized tier 2
approvals completed the study. Further, there were no
substantive differences between tier 1 and tier 2
approved subjects on baseline PANSS total score or any
end point scores.
Subject selection for Alzheimer's disease studies
Clinical trials of AD rely on historical documentation for
progressive cognitive decline to make the diagnosis of
probable AD and do not use a standardized diagnostic
screening instrument like the M.I.N.I. or SCID. Therefore,
the customized C-VISATM batteries for the AD studies
included a narrative historical section to support and
verify the diagnosis. In these studies, the additional
modules included the Clinical Dementia Rating Scale
(CDR), Alzheimer's Disease Assessment Scale-cognitive
part (ADAS-cog), and/or Mini-Mental State Examination
to allow for dual independent scoring of the site-based
recordings [34-36].
In the AD studies, insufficient historical documentation
of progressive cognitive decline was often an administrative
issue that could easily be resolved following queries to
the trial site. Symptom severity scores that were too
low or too high and did not meet the protocol entry
criteria (as measured by dual scoring of the Mini-Mental
State Exam or ADAS-cog) accounted for the majority of
screen failures in the AD studies. The presence of comorbid
medical or psychiatric conditions (e.g., unstable medical
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factors (living conditions, caregiver reliability) were
also frequently identified for tier 2 reviews.
Discussion
This paper describes the application of a novel site-
independent review procedure to affirm subject eligibility
for CNS trials. The Clinical Validation Inventory for Study
Admission (C-VISATM) uses audio-digital recordings of key
site-based screening assessments as the basis for external
(site-independent) eligibility determination. We have devel-
oped a scalable external review procedure that can improve
subject selection and ratings precision for CNS trials,
can be applied in global clinical trials regardless of
language or geography, and does not add subject or
site burden.
As described in this paper, we applied the C-VISATM
review strategy in nine double blind, placebo-controlled
clinical trials across the CNS spectrum. In this meta-
analysis, 16.1% of all 2515 C-VISATM submissions were
challenged by tier 1 reviewers and escalated for further
review. Tier 2 telephone adjudication with the site investi-
gator clarified missing information or resolved clinical
queries and facilitated approval of more than half (58.4%)
of the challenged cases. In fact, more than 72% of cases
challenged for lack of sufficient documentation were
approved after adjudication. Overall, site-independent
reviewers screen failed 6.7% of all submitted C-VISATM
submissions. Some investigators acknowledged privately
that they increased their own level of eligibility diligence
and were reluctant to submit questionable subjects
because of the rigor of the external review process.
Therefore, the mere presence of surveillance may
have abetted some inappropriate submissions.
In all studies, the quality of submitted screen data
improved as a consequence of external review, rater
remediation, and adjudication. The rate of administrative
reviews dropped as trial sites recognized that the adminis-
trative reviewers were actually identifying a lack of sufficient
documentation. Therefore, we believe that the ongoing
surveillance process improved vigilance at the trial sites,
improved documentation, reduced later queries, and
contributed to better subject selection.
The audio-digital recording method was scalable and able
to manage the complexity of global trial sites in Europe
and Asia as well as the United States. Site-independent
reviewers were selected from those regions and were
familiar with the language and cultural issues present
in these populations. The process did not disrupt
clinical or operational procedures at the trial sites.
The data was easily transmitted via a secure website to the
external reviewers, was reviewed quickly without delaying
randomization of appropriate subjects, and did not slow
down the sponsor's enrollment timelines.The use of the C-VISATM surveillance strategy for subject
selection
The C-VISATM workbook includes a battery of key
study eligibility assessments and a summary worksheet
that is customized for each study based upon the
protocol-specific requirements. Generally, the screening
battery incorporates a standardized diagnostic interview
instrument, validated symptomatic measurement scales
that identify the presence and severity of the targeted
symptoms of interest (usually aligned to protocol specific
symptom severity thresholds), a global or functional
assessment measure that requires written documentation
about the presence and clinical relevance of the ‘targeted’
symptoms of interest, and other historical documentation
or treatment history forms to ascertain the appropriate-
ness (validity) of the subject for this specific study.
The external review takes place prior to the baseline visit
(usually randomization) by a site-independent clinical expert
who assesses exactly the same clinical material obtained
and recorded at the site by the site-based interviewer. This
procedure generates a second, site-independent subject
eligibility review that can effectively derail any potential
site-based misincentives that might bias enrollment deci-
sions. The idea that two separate assessments of the same
subject can improve reliability and reduce methodological
errors in clinical trials is not a new concept and has been
applied by other investigators [13,14]. A dual affirmation
strategy improves subject selection and may optimize trial
outcomes [18,31,37].
External review provides an unbiased diagnostic verifica-
tion and symptom severity confirmation to support subject
eligibility. External review is a quality assurance filter to
affirm that the site assessments were appropriately
completed according to the established protocol. Beyond
this obvious surveillance function, the independent
reviewers may identify potentially confounding factors that
could contribute to fluctuating symptom severity and affect
the trial outcome. The potential impact of confounding
factors may be overlooked or underestimated by the
site-based rater assessing the subject for enrollment.
For instance, recent traumatic experiences, geographic
relocations, unstable living conditions, personal losses, or
family crises may be non-specific factors that reduce the
sensitivity of the symptomatic measurements to the experi-
mental drug treatment. Consequently, confounding factors
could impede detection of a significant drug treatment
effect during the clinical trial. A site-independent, unbiased
reviewer is more likely to focus on these potentially con-
founding factors or validity issues than a busy site-based
clinician who is primarily focused on enrollment.
The challenges of subject selection
The three major reasons for screen failure across the CNS
studies in this meta-analysis (regardless of diagnostic
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diagnosis, excluded comorbid psychiatric conditions, and
symptom severity scores that did not meet the protocol
entry criteria thresholds (scores that were either too low
or too high). We have identified several issues that often
lead to eligibility challenges, require adjudication with the
investigator and may result in screen failure:
1. Inadequate documentation to verify the diagnostic
criteria
2. Insufficient or excessive symptom severity
(by protocol-specific criteria)
3. Excluded comorbid medical/psychiatric conditions
or concomitant medications
4. Recent or unsubstantiated acute substance/alcohol
abuse
5. Confounding or destabilizing factors that might
obscure assessment
(a) Dominating extraneous physical or psychic
symptoms
(b) Recent exposure to real or perceived traumatic
events
(c) Unstable social, occupational, or living
conditions
(d) Recent incarceration or hospitalization
6. Lack of clinical validity (relevance)
(a) Presenting symptoms lack sufficient impact on
behavior and/or function (clinical relevance) to
warrant treatment intervention
(b) Lack of a typical clinical presentation consistent
with the known course of the disease (face validity)
7. Unreliable or unassessable subject (e.g., too
disorganized, uncooperative, inconsistent) or
unreliable or unavailable informant (caregiver)
8. Inadequate or insufficient rater interview (may lack
documentation to warrant study eligibility)
9. A lack of a documented treatment history of
response/non-response (in treatment resistant or
partial treatment response studies)
A subject who is truly appropriate (valid) for enrollment
in a clinical trial must have sufficient, measurable,
and clinically relevant symptoms that go beyond the
conventional checklists of the usual protocol inclusion
and exclusion criteria [11,27,28]. The meaning of clinically
relevant symptoms may vary somewhat depending on the
nature of the study. In acute treatment studies, clinical
relevance means that the identified acute symptoms
are measurable and troublesome enough to warrant a
new treatment intervention. Alternatively, in relapse
prevention studies, patients are by definition relatively
stable at the time of enrollment. In AD studies, the
endpoint is generally focused on progressive deterioration
in the absence of effective treatment. In studies that enrollsubjects who are relatively stable (relapse prevention) or
likely to get worse without effective treatment (AD), it is
important to document a pre-treatment history record
that identifies relevant and measurable symptoms that
would affect behavior or function if they recurred or
got worse. In mild to moderate dementia studies, the
presenting cognitive symptoms must have developed
progressively over time, have some current impact on
behavior or function, and be likely to progress further in
the absence of an effective anti-dementia treatment.
Recently, studies of prodromal AD have made subject
selection by history less relevant because they seek
patients without evidence of progressive decline or
current functional impact and seek biomarkers of
relevance instead.
The use of audio-digital recording of site-based
interviews
We used an audio-digital pen recorder to record and
review the site-based interviews. A computer tablet
may also be used for this purpose although the pen is less
obtrusive than a tablet and a more familiar object during
an interview. The procedure is similar to the usual pen on
paper interview and requires no additional props.
The site-based recording method does not require a
separate, second interview because it simultaneously
records the audio and written (digital) components of
the actual site-based interview. The site-independent
clinical rater is able to hear the interview and read the
written notes to score symptoms by using exactly the
same data obtained by the site-based rater. The dual
assessments are based upon the same questions and
the same subject responses given at the same time to
the site-based rater. In addition, the process is less
burdensome to the site than a second, remote interview
and is not subject to the informational or temporal
variance that would be generated by a separate interview.
The recording of site-based interviews is a form of
quality assurance. The mere existence of an external
surveillance system of this kind has a salutary effect on
the quality of screening assessments. Independent review
of the recordings can confirm that there was a complete
and competent site-based interview done. Inadequate
interviews lead to rater remediation and can improve
performance and enhance the integrity of study data.
Beyond rating competency, the recordings permit
entirely independent dual scoring of key rating instruments
to assess scoring accuracy. The replication of site-based
scores by a blinded, independent rater can not only affirm
site-based ratings competency but also demonstrate rating
precision [38].
The required recordings compel site-based interviewers
to explore unanticipated validity issues that emerge during
interviews that might have been skipped over without a
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fully aware that a potentially confounding issue that might
obscure accurate assessment cannot be ignored because
the dual reviewer may uncover the issue. For instance, the
possibility of secondary gain as the motive to seek study
entry (e.g., payments), or current substance abuse, if
casually raised by the subject during the interview, must
now be fully explored. Similarly, any recent traumatic
experiences or acute stressors or abrupt life cycle changes
that may have triggered the acute symptoms and might
obscure accurate assessment during a trial must be
clarified in order to justify subject eligibility.The use of adjudication with the site investigator
Adjudication between the tier 2 reviewer and site-based
investigator is required whenever an independent review
of subject eligibility is challenged. Adjudication improves
the precision of the subject selection process by inviting
collaboration with the trial sites, providing remediation
as needed, and reinforcing good clinical practice.
It is self-evident that an audio recording may not
capture the full clinical picture or prevailing external
circumstances for every potential subject. Therefore,
telephonic adjudication with the site investigator is
necessary and often useful for elaboration and clarification
of historical and clinical information. The site-based
investigator may be aware of additional information that
warrants study eligibility. For instance, a subject may
describe an apparent confounding factor (e.g., a recent
move from one city to another or the illness of a parent)
that may or may not be clinically relevant during the trial.
Sometimes, the recorded site-based interview lacks
sufficient information to verify the diagnosis, to con-
firm the presence or impact of important symptoms
(e.g., delusions), or to evaluate the clinical relevance of
recent changes in the subject's life. In the meta-analysis of
the nine studies presented here, more than half of the
tier 2 reviews were ultimately approved after telephone
adjudication with the site investigator.
In our experience, telephone adjudication is a form of
education and remediation. In the studies reviewed in
this meta-analysis, the adjudication process had the
interesting remedial effect of improving screen documenta-
tion for all submissions that followed adjudication discus-
sions. As noted above, some investigators acknowledged
that they increased their own level of eligibility diligence
because of the rigor of the external review process.Limitations of the C-VISATM method
Two obvious limitations of the C-VISATM method are
(1) dependency on site-based rater competency and (2)
reliance on audio-digital recordings as opposed to live
interviews for the site-independent review.Site-based ratings competency
It is obvious that the dual scoring method requires a
competent site-based rater who is trained to conduct
research interviews, administers complete interviews,
and is willing to use an audio-digital recording device.
The independent reviewer can query the site for more
information but cannot interview the subject.
Rater training and certification conducted prior to
a study does not necessarily equate with competent
in-study interviews done with real study patients. The
audio-recordings can identify incompetent or inadequate
interviews and can lead to rater remediation. In most
cases, site-based interviews provide sufficient data and
yield high scoring correlations with the site-independent
dual scores [39]. In some cases, the site-based rater cannot
learn to conduct adequate interviews and must be
replaced despite efforts at remediation.
Kobak and colleagues cautioned that unregulated
site-based interviews might be inadequate and briefer
than necessary to obtain sufficient clinical data [9]. In
our experience, the requisite recording procedure and
remediation efforts have actually improved the quality and
integrity of the site-based interview and reinforced
competent and full assessments.
C-VISATM reliance on audio-digital recordings
In some studies, the audio-digital method of capturing
historical and clinical information will not be sufficient
to evaluate subject eligibility. For instance, an audio
recording can ask questions but cannot capture the
clinical observations made by a live interviewer about
psychomotor retardation. A video recording may be
needed in order to capture the visual appearance and
behavioral responses that occur during the interview or to
observe motor examinations (e.g., Parkinson's disease).
Neither audio- nor video-referenced assessments can
fully capture the clinical nuance of a live face-to-face
interview. For this reason, the adjudication discussion
with the investigator is an essential part of the subject
selection review process because it allows the independent
reviewer to obtain more specific documentation and to
clarify clinical information that may not be apparent on an
audio or video recording (or during a telephone interview).
Non-specific factors affecting trial outcomes
Subject selection for CNS trials is a complex process that
relies on the collection of accurate historical information
and symptomatic data collected from an ill subject by a
competent assessor. Clearly, there are limits to the precision
of both diagnostic and symptom severity assessments for
CNS diseases [11,28,40,41]. Non-specific, extraneous factors
unrelated to the experimental drug treatment might affect
subject behavior or performance and obscure accurate
assessments at the screen visit and during the study as well.
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candidate drug might account for more than 75% of the
observed improvement in drug-treated groups in random-
ized clinical trials for MDD [42,43]. The C-VISATM strategy
is a systematic external review process that attempts to
weed out some of these non-specific factors and reinforce
data integrity. Although the C-VISATM may reduce
some of the manageable signal noise inherent in a
double-blind clinical trial, it cannot eliminate all of
the possible non-specific factors that are unrelated to
drug treatment.
Summary and conclusions
The C-VISATM process provides an unbiased, site-
independent eligibility review strategy to confirm site-based
assessments prior to randomization. As described in this
meta-analysis, The C-VISATM provided an independent
clinical assessment of the recorded site-based screening
interviews. The recording process eliminated the need for
an entirely separate interview and was a cost-effective and
time-efficient method for use in these clinical trials.
The C-VISATM is essentially a quality assurance strategy
that seeks to minimize the potential ‘noise’ that can
adversely affect clinical trial outcomes. The recording
method is scalable and can therefore be used in global,
multi-national studies regardless of regional location or
language.
The C-VISATM external review method (1) identifies
unreliable subjects and incompetent raters, (2) provides
site-independent diagnostic verification, (3) provides
symptom severity confirmation based upon dual scoring
of recorded site-based interviews, (4) documents and
affirms subject validity for the study, and (5) rules out the
presence of comorbid conditions or confounding factors
that might obscure the accurate assessment of symptoms
during the study interval.
The C-VISATM review process coupled with dual inde-
pendent scoring of key rating instruments is a quality assur-
ance strategy that provides a systematic site-independent
eligibility filter to enhance the precision of subject selection
and the integrity of study data. The process insists on
appropriate documentation and a keener focus on accurate
measurement of pre-randomization symptom severity. This
customized audio-digital recording method is scalable and
has been able to accommodate phase II and III global trials
that use trial sites in Europe and Asia as well as the United
States. The C-VISATM strategy has broad applicability
across the CNS spectrum because it achieves the objective
of confirmatory site-independent review without producing
excessive site or subject burden.
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